Literature DB >> 18563320

Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression.

Jinjian Yao1, Weiling Yu, Ying Chang, Jinghua Ren, Dong Xu, Siyuan Han, Jusheng Lin.   

Abstract

In order to screen potential mRNA locations of P gene in which targeting siRNAs can effectively inhibit HBV expression, 5 recombinant plasmids containing 4 targeting-specific siRNA fragments and a control were prepared and transfected into 2.2.15 cells respectively. The expression levels of HBx mRNA, HBs mRNA and HBc mRNA were detected by RT-PCR. The concentrations of the hepatitis B virus antigens, including HBsAg and HBeAg harvested from the culture supernatant of transfected 2.2.15 cells, were measured by ELISA. X protein was tested by Western blot. The results showed that four siRNAs against distinct mRNA locations of HBV polymerase gene had different inhibitory effects on their targeted mRNA. The plasmid-derived psiRNA1 and psiRNA2 could effectively inhibit the transcription and translation of HBs gene, whereas the inhibitory efficiency of psiRNA3, psiRNA4 for HBe gene was much higher than that of psiRNA1 and psiRNA2. In comparison to the rest of psiRNAs in this study, psiRNA4 was the most effective to suppress the transcription and translation of HBx. It is suggested that siRNA can be considered as a powerful therapeutic agent for reducing HBV expression. The siRNAs against HBV polymerase are effective largely depending on the location of targeted sites. To enhance inhibitory efficiency, hunting for high effective target in polymerase gene is necessary and feasible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563320     DOI: 10.1007/s11596-008-0308-1

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  25 in total

1.  Functional siRNAs and miRNAs exhibit strand bias.

Authors:  Anastasia Khvorova; Angela Reynolds; Sumedha D Jayasena
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

2.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.

Authors:  David V Morrissey; Karin Blanchard; Lucinda Shaw; Kristi Jensen; Jennifer A Lockridge; Brent Dickinson; James A McSwiggen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Barry A Polisky; Shawn Zinnen
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

3.  Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

Authors:  C L Lai; C K Ching; A K Tung; E Li; J Young; A Hill; B C Wong; J Dent; P C Wu
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

4.  Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein.

Authors:  Sladjana Gagrica; Stefanie Hauser; Ingrid Kolfschoten; Lisa Osterloh; Reuven Agami; Stefan Gaubatz
Journal:  EMBO J       Date:  2004-11-11       Impact factor: 11.598

5.  Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy.

Authors:  V Carreño; I Castillo; J Molina; J C Porres; J Bartolomé
Journal:  J Hepatol       Date:  1992-05       Impact factor: 25.083

6.  Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.

Authors:  Christian Klein; C Thomas Bock; Heiner Wedemeyer; Torsten Wüstefeld; Stephen Locarnini; Hans Peter Dienes; Stefan Kubicka; Michael P Manns; Christian Trautwein
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

7.  Specific hepatitis B virus minus-strand DNA synthesis requires only the 5' encapsidation signal and the 3'-proximal direct repeat DR1.

Authors:  A Rieger; M Nassal
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  siRNA-mediated inhibition of HBV replication and expression.

Authors:  Xiao-Nan Zhang; Wei Xiong; Jia-Dong Wang; Yun-Wen Hu; Li Xiang; Zheng-Hong Yuan
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

9.  Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.

Authors:  Yu-Wei Leu; Pearlly S Yan; Meiyun Fan; Victor X Jin; Joseph C Liu; Edward M Curran; Wade V Welshons; Susan H Wei; Ramana V Davuluri; Christoph Plass; Kenneth P Nephew; Tim H-M Huang
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

10.  Modulation of HIV-1 replication by RNA interference.

Authors:  Jean-Marc Jacque; Karine Triques; Mario Stevenson
Journal:  Nature       Date:  2002-06-26       Impact factor: 69.504

View more
  3 in total

1.  RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level.

Authors:  Jinghua Ren; Wenshan He; Ruiguang Zhang; Zhenyu Li; Wenmiao Cao; Jie Yao; Fang Zhu; Tao Zhang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

2.  PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication.

Authors:  Lixia Gao; Jie Yang; Jutao Feng; Ziying Liu; Ying Dong; Jiangyan Luo; Liangzhentian Yu; Jiamei Wang; Hongying Fan; Weifeng Ma; Tiancai Liu
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

Review 3.  Development and application of ribonucleic acid therapy strategies against COVID-19.

Authors:  Lin Ning; Mujiexin Liu; Yushu Gou; Yue Yang; Bifang He; Jian Huang
Journal:  Int J Biol Sci       Date:  2022-08-01       Impact factor: 10.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.